Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2
Autor: | David P, Burns, Jane, Rowland, Leonie, Canavan, Kevin H, Murphy, Molly, Brannock, Dervla, O'Malley, Ken D, O'Halloran, Deirdre, Edge |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
Nonmuscle Myosin Type IIB Myosin Heavy Chains Corticotropin-Releasing Hormone Muscle Fibers Skeletal Antibodies Neutralizing Receptors Interleukin-6 Respiratory Muscles Dystrophin Muscular Dystrophy Duchenne Disease Models Animal Interferon-gamma Mice Mice Inbred mdx Pharyngeal Muscles Animals Female Urocortins Muscle Contraction |
Zdroj: | Experimental physiology. 102(9) |
ISSN: | 1469-445X |
Popis: | What is the central question of this study? We previously reported impaired upper airway dilator muscle function in the mdx mouse model of Duchenne muscular dystrophy (DMD). Our aim was to assess the effect of blocking interleukin-6 receptor signalling and stimulating corticotrophin-releasing factor receptor 2 signalling on mdx sternohyoid muscle structure and function. What is the main finding and its importance? The interventional treatment had a positive inotropic effect on sternohyoid muscle force, restoring mechanical work and power to wild-type values, reduced myofibre central nucleation and preserved the myosin heavy chain type IIb fibre complement of mdx sternohyoid muscle. These data might have implications for development of pharmacotherapies for DMD with relevance to respiratory muscle performance. The mdx mouse model of Duchenne muscular dystrophy shows evidence of impaired pharyngeal dilator muscle function. We hypothesized that inflammatory and stress-related factors are implicated in airway dilator muscle dysfunction. Six-week-old mdx (n = 26) and wild-type (WT; n = 26) mice received either saline (0.9% w/v) or a co-administration of neutralizing interleukin-6 receptor antibodies (0.2 mg kg |
Databáze: | OpenAIRE |
Externí odkaz: |